Thierry Abribat, Founder and CEO, Amolyt Pharma is developing a portfolio of products of peptides for rare endocrine and metabolic disorders.  Their first project is a peptide hormone that is a parathyroid hormone being developed to treat hypoparathyroidism, a condition most often suffered by middle aged women and likely caused by thyroid surgery when the parathyroid glands are also removed.  The alternate treatment being developed will address the current short term and long term burden these patients are facing with conventional therapy by better managing blood calcium, decreasing elimination of calcium through the kidneys and maintaining bone integrity.

@AmolytPharma

#TherapeuticPeptides #RareDiseases #EndocrineDisease #MetabolicDisease #Endocrinology #Hypoparathyroidism #Hypopara

AmolytPharma.com

Listen to the podcast here.